IMPACT BIOMEDICAL INC.
For the period ended Dec 31, 2024. Filed Mar 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 28, 2025
IBO$4.33+5.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
As of December 31,
| 2024 | 2023 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $1,999,000 | $1,000 |
| Other receivables | - | 128,000 |
| Current portion of notes receivable | 184,000 | 203,000 |
| Prepaid expenses and other current assets | 265,000 | - |
| Total current assets | 2,448,000 | 332,000 |
| Property, plant and equipment, net | 17,000 | 287,000 |
| Notes receivable | 17,000 | - |
| Goodwill | - | 25,093,000 |
| Other intangible assets, net | 17,808,000 | 18,921,000 |
| Total assets | $20,290,000 | $44,633,000 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $713,000 | $832,000 |
| Accrued expenses | 194,000 | 230,000 |
| Note payable, related party | 8,878,000 | 12,074,000 |
| Total current liabilities | 9,785,000 | 13,136,000 |
| Deferred tax liability, net | 3,268,000 | 3,235,000 |
| Total liabilities | 13,053,000 | 16,371,000 |
| Commitments and contingencies (Note 12) | - | - |
| Stockholders’ equity | ||
| Preferred stock, $.001 par value; 100,000,000 shares authorized, 60,496,041 shares issued and outstanding (60,496,041 on December 31, 2023); Liquidation value $0.001 per share, $60,000 aggregate. $60,000 on December 31, 2023). | 60,000 | 60,000 |
| Common stock, $.001 par value; 4,000,000,000 shares authorized, 11,503,955 shares issued and outstanding (10,000,000 on December 31, 2023) | 11,000 | 10,000 |
| Additional paid-in capital | 41,857,000 | 38,113,000 |
| Accumulated deficit | (37,669,000) | (12,961,000) |
| Total stockholders’ equity of the Company | 4,259,000 | 25,222,000 |
| Non-controlling interest in subsidiaries | 2,978,000 | 3,040,000 |
| Total stockholders’ equity | 7,237,000 | 28,262,000 |
| Total liabilities and stockholders’ equity | $20,290,000 | $44,633,000 |
**I
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.